Live feed
·
PRReleasevia Quantisnow
Adial Pharmaceuticals Inc logo

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

ByQuantisnow·Wall Street's wire, on your screen.
ADIL· Adial Pharmaceuticals Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADIL (Adial Pharmaceuticals Inc) and more on Quantisnow.